12.2 Local Anesthetic Systemic Toxicity (LAST): Recognition, Lipid Emulsion & Resuscitation

Local Anesthetic Systemic Toxicity (LAST): Recognition, Lipid Emulsion & Resuscitation

Core Principle: Local Anesthetic Systemic Toxicity (LAST) is a life-threatening iatrogenic complication triggered by accidental intravascular injection or rapid systemic vascular absorption of local anesthetic agents. In the ambulatory surgery center—where peripheral nerve blocks, tumescent infiltration, and regional field blocks are ubiquitous—the perioperative nurse must recognize early subjective neurological warning signs and immediately deploy 20% lipid emulsion therapy with modified ACLS resuscitation algorithms to avert fatal refractory cardiac arrest.

---

Local Anesthetic Classification & Molecular Pathophysiology

Local anesthetics reversibly block voltage-gated sodium channels (Nav1.5 in cardiac myocytes and Nav1.1–1.6 in peripheral nerves), preventing the rapid influx of sodium ions necessary for cellular depolarization and action potential propagation. Structurally, local anesthetics consist of a lipophilic aromatic ring, an intermediate chain, and a hydrophilic amine group. The chemical linkage of the intermediate chain categorizes them into two distinct classes:

The "I" Before "-Caine" Rule

• Amino-Amides (Two "i"s): Contain an amide linkage (-NH-CO-) and have two "i"s in their generic name: Lidocaine, Bupivacaine, Ropivacaine, Mepivacaine, Prilocai**ne. Amides are metabolized primarily in the liver by microsomal cytochrome P450 enzymes (CYP1A2 and CYP3A4). Factors that impair hepatic perfusion or function (cirrhosis, congestive heart failure, hypothermia) dramatically prolong their half-life and compound accumulation risk.
• Amino-Esters (One "i"): Contain an ester linkage (-CO-O-) and have only one "i" in their generic name: Procaine, Chloroprocaine, Tetracaine, Cocaine. Esters are rapidly hydrolyzed in plasma by pseudocholinesterase (butyrylcholinesterase) into para-aminobenzoic acid (PABA) derivatives, accounting for higher allergic potential but shorter systemic half-lives.

The Bupivacaine Cardiotoxicity Hazard

Among local anesthetics, bupivacaine (Marcaine, Sensorcaine) carries the highest cardiotoxicity-to-neurotoxicity ratio. Bupivacaine is highly lipophilic (heptane:water partition coefficient >300) and exhibits profound stereoselective binding to cardiac sodium channels. Unlike lidocaine, which binds rapidly during systole and unbinds rapidly during diastole ("fast-in, fast-out"), bupivacaine enters sodium channels during systole but dissociates extremely slowly during diastole ("fast-in, slow-out" kinetics). At physiological heart rates, bupivacaine accumulates progressively in the sodium channels, precipitating intractable conduction delays, prolonged QRS complexes, ventricular arrhythmias (ventricular tachycardia, torsades de pointes), and electromechanical dissociation (PEA) that resists standard electrical defibrillation.

---

Maximum Weight-Based Dosing & Epinephrine Markers

Toxic systemic concentrations occur when the rate of drug absorption into the vascular tree exceeds the rate of tissue redistribution and hepatic/plasma clearance. The perioperative nurse must independently calculate and verify the total cumulative dose administered by the surgical and anesthesia team across all anatomical sites.

The Role of Epinephrine as a Vascular Marker

Adding epinephrine (typically at a concentration of 1:200,000 = 5 mcg/mL) achieves two critical safety objectives:

1. Local Vasoconstriction: Epinephrine constricts local precapillary sphincters, delaying systemic vascular absorption, lowering peak systemic plasma concentrations (Cmax) by 30% to 50%, and extending block duration.
2. Intravascular Injection Marker: An accidental intravascular injection of an epinephrine-containing local anesthetic test dose produces a rapid, transient heart rate increase of ≥10–20 bpm or a systolic blood pressure rise of ≥15 mmHg within 30 to 60 seconds. In patients taking beta-blockers, an accidental intravascular injection may manifest as an abrupt systolic blood pressure surge of ≥15–20 mmHg or sudden T-wave amplitude changes rather than tachycardia.

---

Clinical Presentation: The Biphasic Progression of LAST

Classically, LAST presents in a biphasic sequence, wherein central nervous system (CNS) symptoms precede cardiovascular (CV) collapse. However, in modern practice—particularly with high-dose bupivacaine or when patients receive heavy intravenous sedation (midazolam, propofol, fentanyl)—initial CNS warning signs may be completely masked, and the crisis may present abruptly as sudden cardiovascular collapse.

┌────────────────────────────────────────────────────────────────────────┐
│                     BIPHASIC PROGRESSION OF LAST                       │
├────────────────────────────────────────────────────────────────────────┤
│ PHASE 1: CENTRAL NERVOUS SYSTEM (CNS) TOXICITY                         │
│  ↳ Subjective Prodromes: Perioral numbness, metallic/bitter taste,     │
│    circumoral tingling, auditory tinnitus, blurred/double vision,     │
│    dizziness, lightheadedness, apprehension, agitation, talkativeness. │
│  ↳ Objective Excitation: Facial and digit muscle twitching, tremors,   │
│    shivering, progressing to generalized tonic-clonic convulsions.     │
│  ↳ CNS Depression: Progressive lethargy, loss of consciousness, coma,  │
│    bradypnea, complete respiratory arrest (apnea).                     │
├────────────────────────────────────────────────────────────────────────┤
│ PHASE 2: CARDIOVASCULAR (CV) TOXICITY                                  │
│  ↳ Initial Hyperdynamic Phase: Transient hypertension and tachycardia  │
│  ↳ Conduction Deficits: Prolonged PR interval, widening QRS complexes, │
│    bundle branch blocks, AV dissociation.                              │
│  ↳ Severe Hypodynamic Collapse: Myocardial depression, profound       │
│    hypotension, severe bradycardia, ventricular tachycardia (VT),      │
│    ventricular fibrillation (VF), torsades de pointes, and asystole.  │
└────────────────────────────────────────────────────────────────────────┘

Why CNS Toxicity Precedes Cardiac Toxicity

Local anesthetics cross the blood-brain barrier rapidly. At low toxic blood concentrations, they preferentially inhibit inhibitory cortical interneurons (GABAergic pathways). Without inhibitory control, excitatory neuronal pathways fire unopposed, producing the excitatory prodrome (agitation, muscle twitching, seizures). As plasma concentrations climb further, both inhibitory and excitatory pathways are completely paralyzed, culminating in generalized CNS depression, coma, and apnea.

---

The ASRA LAST Emergency Management Protocol

The American Society of Regional Anesthesia and Pain Medicine (ASRA) provides evidence-based practice guidelines for managing LAST. The perioperative team must execute these life-saving interventions without hesitation.

1. Immediate Cessation & Alarm Activation

• Stop injecting local anesthetic immediately. Disconnect syringes and catheters.
• Call for help, crash cart, and the dedicated LAST Rescue Kit (containing 20% lipid emulsion, large-bore IV tubing, and dosing checklists).

2. Airway Management, Oxygenation & Ventilation

• Establish a secure airway immediately and ventilate with 100% oxygen via bag-valve-mask or endotracheal tube.
• Avoid Hyperventilation: Hyperventilation induces hypocapnia (PaCO₂ <30 mmHg), which triggers cerebral vasoconstriction, reduces cerebral blood flow, and impairs brain oxygen delivery.
• Avoid Hypoventilation and Acidosis: Conversely, hypoventilation produces hypercapnia and respiratory acidosis. Acidosis increases the percentage of ionized, free active local anesthetic drug and lowers the seizure threshold. The anesthesia team must ventilate to achieve normocarbia (PaCO₂ 35–45 mmHg).

3. Seizure Suppression Protocol

Seizures dramatically escalate metabolic consumption, worsen lactic acidosis, and aggravate hyperkalemia, compounding cardiac toxicity. Seizures must be halted within seconds:

• First-Line Therapy: Benzodiazepines. Administer Midazolam 1 to 2 mg IV, titrated rapidly. Benzodiazepines enhance GABA-mediated inhibition without depressing cardiac inotropy.
• Caution with Propofol: While propofol possesses anticonvulsant properties, it is a potent negative inotrope and systemic vasodilator. Propofol must be strictly avoided if the patient exhibits any signs of hemodynamic instability, bradycardia, or hypotension.
• Neuromuscular Blockers (Succinylcholine or Rocuronium): May be administered to eliminate muscular convulsions, facilitate tracheal intubation, and halt lactic acid generation from violent shivering, but neuromuscular blockers do not stop central epileptiform electrical seizure activity in the brain.

4. 20% Lipid Emulsion Therapy (Intralipid)

Intravenous 20% lipid emulsion is the specific physiological antidote for local anesthetic toxicity. It should be initiated at the earliest sign of systemic toxicity—do not wait for full cardiac arrest!

Mechanisms of Action

1. The "Lipid Sink" (Partitioning) Effect: The infused lipid droplets create a vast intravascular hydrophobic lipid compartment that binds and extracts lipophilic local anesthetic molecules from target tissues (heart and brain) down a concentration gradient, sequestering them in blood for clearance.
2. Metabolic Substrate Restoration: Bupivacaine inhibits carnitine acyltransferase-1, blocking mitochondrial uptake of long-chain fatty acids (the heart's primary energy source). Exogenous lipid emulsion overrides this block, replenishing mitochondrial ATP synthesis in starved cardiac myocytes.
3. Membrane & Inotropic Channel Effects: Lipid infusion increases intracellular calcium concentration in cardiac myocytes, directly exerting a positive inotropic effect and opening inactivated voltage-gated sodium channels.

Dosing and Administration Algorithm

Use the current ASRA LAST checklist kept with the rescue kit:

• Adults approximately 70 kg or more: Give about 100 mL of 20% lipid emulsion over 2 to 3 minutes, then infuse about 250 mL over 15 to 20 minutes.
• Patients under 70 kg: Give 1.5 mL/kg over 2 to 3 minutes, then infuse 0.25 mL/kg/min.
• If instability persists: Repeat the bolus and double the infusion rate as directed by the checklist.
• Maximum cumulative dose: 12 mL/kg.

Continue monitoring after stabilization. ASRA’s checklist uses at least 2 hours of observation after a seizure-only event and 4 to 6 hours after cardiovascular instability. Arrange hospital transfer because recurrence or delayed deterioration can occur.

5. Critical ACLS Modifications in LAST Resuscitation

Standard Advanced Cardiovascular Life Support (ACLS) guidelines must be significantly altered during local anesthetic cardiac arrest. Applying standard ACLS blindly causes devastating outcomes.

• Reduce Epinephrine Bolus Doses to ≤1 mcg/kg (e.g., 10 to 100 mcg IV boluses): Standard ACLS 1.0 mg epinephrine boluses produce extreme myocardial adrenergic stimulation, trigger intractable ventricular arrhythmias, worsen lactic acidosis, and impair lipid emulsion resuscitation. Titrate tiny doses (10–100 mcg) to support coronary perfusion pressure.
• STRICTLY AVOID Vasopressin: Vasopressin causes severe myocardial ischemia, triggers pulmonary edema, and worsens resuscitation survival in LAST animal models.
• STRICTLY AVOID Calcium Channel Blockers & Beta-Blockers: Severely compound local anesthetic-induced negative inotropy and conduction delays.
• STRICTLY CONTRAINDICATED: Local Anesthetic Antiarrhythmics: Lidocaine and Procainamide must never be given for ventricular arrhythmias during LAST! Administering lidocaine introduces additional sodium channel blockers into an already poisoned myocardium.
• Amiodarone is First-Line for Dysrhythmias: For ventricular tachycardia (VT) or ventricular fibrillation (VF), administer Amiodarone (150 to 300 mg IV).
• Prepare for Prolonged CPR: Because local anesthetics slowly clear from cardiac tissue, chest compressions and continuous life support must be maintained for 60 minutes or longer until lipid emulsion sequesters the drug.
• Extracorporeal Membrane Oxygenation (ECMO): Alert local tertiary facilities early. If available, venoarterial (VA) ECMO or cardiopulmonary bypass serves as a bridge to survival until myocardial clearance occurs.
• Observation Timelines: Patients exhibiting mild CNS symptoms must be monitored continuously for at least 2 hours. Patients experiencing cardiovascular collapse or seizures require continuous monitoring in an ICU for at least 4 to 6 hours.